Treatment of elderly and unfit patients with CRC

Hans Prenen obtained his medical degree and PhD at the Catholic University Leuven. He is currently the head of the Medical Oncology Department at the University Hospital Antwerp and director of the Oncology Clinical Trial Unit. He is member of several scientific organisations including the Belgian Society of Medical Oncology (board member since 2015) and the European Society of Medical oncology (scientific committee). He is a recognised international expert in the field of cancer and is regularly invited to national and international meetings and has published more than 160 peer reviewed scientific papers. He is principal investigator of several clinical trials with a focus on phase 1 and basket trials. His research interests relate to translational studies on targeted therapies, new anticancer therapies and understanding the molecular changes induced by anticancer therapy.

Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota.  She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. 

Assoc. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory boards: Bayer, Merck, BeiGene, Incyte

Research funding to institution: Merck, Boston Biomedical, Treos Bio, Senhwa Pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche